Timothy E McAlindon1, Michael P LaValley2, William F Harvey1, Lori Lyn Price3, Jeffrey B Driban1, Ming Zhang1, Robert J Ward4. 1. Division of Rheumatology, Tufts Medical Center, Boston, Massachusetts. 2. Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts. 3. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts4Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts. 4. Division of Musculoskeletal Imaging and Intervention, Tufts Medical Center, Boston, Massachusetts.
Abstract
IMPORTANCE: Synovitis is common and is associated with progression of structural characteristics of knee osteoarthritis. Intra-articular corticosteroids could reduce cartilage damage associated with synovitis but might have adverse effects on cartilage and periarticular bone. OBJECTIVE: To determine the effects of intra-articular injection of 40 mg of triamcinolone acetonide every 3 months on progression of cartilage loss and knee pain. DESIGN, SETTING, AND PARTICIPANTS: Two-year, randomized, placebo-controlled, double-blind trial of intra-articular triamcinolone vs saline for symptomatic knee osteoarthritis with ultrasonic features of synovitis in 140 patients. Mixed-effects regression models with a random intercept were used to analyze the longitudinal repeated outcome measures. Patients fulfilling the American College of Rheumatology criteria for symptomatic knee osteoarthritis, Kellgren-Lawrence grades 2 or 3, were enrolled at Tufts Medical Center beginning February 11, 2013; all patients completed the study by January 1, 2015. INTERVENTIONS: Intra-articular triamcinolone (n = 70) or saline (n = 70) every 12 weeks for 2 years. MAIN OUTCOMES AND MEASURES: Annual knee magnetic resonance imaging for quantitative evaluation of cartilage volume (minimal clinically important difference not yet defined), and Western Ontario and McMaster Universities Osteoarthritis index collected every 3 months (Likert pain subscale range, 0 [no pain] to 20 [extreme pain]; minimal clinically important improvement, 3.94). RESULTS: Among 140 randomized patients (mean age, 58 [SD, 8] years, 75 women [54%]), 119 (85%) completed the study. Intra-articular triamcinolone resulted in significantly greater cartilage volume loss than did saline for a mean change in index compartment cartilage thickness of -0.21 mm vs -0.10 mm (between-group difference, -0.11 mm; 95% CI, -0.20 to -0.03 mm); and no significant difference in pain (-1.2 vs -1.9; between-group difference, -0.6; 95% CI, -1.6 to 0.3). The saline group had 3 treatment-related adverse events compared with 5 in the triamcinolone group and had a small increase in hemoglobin A1c levels (between-group difference, -0.2%; 95% CI, -0.5% to -0.007%). CONCLUSIONS AND RELEVANCE: Among patients with symptomatic knee osteoarthritis, 2 years of intra-articular triamcinolone, compared with intra-articular saline, resulted in significantly greater cartilage volume loss and no significant difference in knee pain. These findings do not support this treatment for patients with symptomatic knee osteoarthritis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01230424.
IMPORTANCE: Synovitis is common and is associated with progression of structural characteristics of knee osteoarthritis. Intra-articular corticosteroids could reduce cartilage damage associated with synovitis but might have adverse effects on cartilage and periarticular bone. OBJECTIVE: To determine the effects of intra-articular injection of 40 mg of triamcinolone acetonide every 3 months on progression of cartilage loss and knee pain. DESIGN, SETTING, AND PARTICIPANTS: Two-year, randomized, placebo-controlled, double-blind trial of intra-articular triamcinolone vs saline for symptomatic knee osteoarthritis with ultrasonic features of synovitis in 140 patients. Mixed-effects regression models with a random intercept were used to analyze the longitudinal repeated outcome measures. Patients fulfilling the American College of Rheumatology criteria for symptomatic knee osteoarthritis, Kellgren-Lawrence grades 2 or 3, were enrolled at Tufts Medical Center beginning February 11, 2013; all patients completed the study by January 1, 2015. INTERVENTIONS: Intra-articular triamcinolone (n = 70) or saline (n = 70) every 12 weeks for 2 years. MAIN OUTCOMES AND MEASURES: Annual knee magnetic resonance imaging for quantitative evaluation of cartilage volume (minimal clinically important difference not yet defined), and Western Ontario and McMaster Universities Osteoarthritis index collected every 3 months (Likert pain subscale range, 0 [no pain] to 20 [extreme pain]; minimal clinically important improvement, 3.94). RESULTS: Among 140 randomized patients (mean age, 58 [SD, 8] years, 75 women [54%]), 119 (85%) completed the study. Intra-articular triamcinolone resulted in significantly greater cartilage volume loss than did saline for a mean change in index compartment cartilage thickness of -0.21 mm vs -0.10 mm (between-group difference, -0.11 mm; 95% CI, -0.20 to -0.03 mm); and no significant difference in pain (-1.2 vs -1.9; between-group difference, -0.6; 95% CI, -1.6 to 0.3). The saline group had 3 treatment-related adverse events compared with 5 in the triamcinolone group and had a small increase in hemoglobin A1c levels (between-group difference, -0.2%; 95% CI, -0.5% to -0.007%). CONCLUSIONS AND RELEVANCE: Among patients with symptomatic knee osteoarthritis, 2 years of intra-articular triamcinolone, compared with intra-articular saline, resulted in significantly greater cartilage volume loss and no significant difference in knee pain. These findings do not support this treatment for patients with symptomatic knee osteoarthritis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01230424.
Authors: Yuqing Zhang; Ryan Woods; Christine E Chaisson; Tuhina Neogi; Jingbo Niu; Timothy E McAlindon; David Hunter Journal: Am J Med Date: 2006-09 Impact factor: 4.965
Authors: Jeannie Chao; Christopher Wu; Bob Sun; Michal Kalli Hose; Anna Quan; Tudor H Hughes; David Boyle; Kenneth C Kalunian Journal: J Rheumatol Date: 2010-01-15 Impact factor: 4.666
Authors: C G Peterfy; A Guermazi; S Zaim; P F J Tirman; Y Miaux; D White; M Kothari; Y Lu; K Fye; S Zhao; H K Genant Journal: Osteoarthritis Cartilage Date: 2004-03 Impact factor: 6.576
Authors: Reva C Lawrence; David T Felson; Charles G Helmick; Lesley M Arnold; Hyon Choi; Richard A Deyo; Sherine Gabriel; Rosemarie Hirsch; Marc C Hochberg; Gene G Hunder; Joanne M Jordan; Jeffrey N Katz; Hilal Maradit Kremers; Frederick Wolfe Journal: Arthritis Rheum Date: 2008-01
Authors: Raveendhara R Bannuru; Timothy E McAlindon; Matthew C Sullivan; John B Wong; David M Kent; Christopher H Schmid Journal: Ann Intern Med Date: 2015-09-01 Impact factor: 25.391
Authors: Ming Zhang; Jeffrey B Driban; Lori Lyn Price; Grace H Lo; Eric Miller; Timothy E McAlindon Journal: Biomed Res Int Date: 2015-12-02 Impact factor: 3.411
Authors: A J Grodzinsky; R M Porter; A G Bajpayee; R E De la Vega; M Scheu; N H Varady; I A Yannatos; L A Brown; Y Krishnan; T J Fitzsimons; P Bhattacharya; E H Frank Journal: Eur Cell Mater Date: 2017-12-05 Impact factor: 3.942
Authors: Brett C Geiger; Sheryl Wang; Robert F Padera; Alan J Grodzinsky; Paula T Hammond Journal: Sci Transl Med Date: 2018-11-28 Impact factor: 17.956
Authors: Ian A Jones; Melissa Wilson; Ryan Togashi; Bo Han; Austin K Mircheff; C Thomas Vangsness Journal: BMC Musculoskelet Disord Date: 2018-10-24 Impact factor: 2.362
Authors: Shao-Hsien Liu; Catherine E Dubé; Charles B Eaton; Jeffrey B Driban; Timothy E McAlindon; Kate L Lapane Journal: J Rheumatol Date: 2018-06-15 Impact factor: 4.666